Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Araclon Biotech Selects MedAvante Virgil Platform for Phase 2 Alzheimer’s Trial

By Drug Discovery Trends Editor | April 10, 2017

 Araclon Biotech, a Grifols company dedicated to the research and development of therapies and diagnostic methods to be applied to degenerative diseases, and MedAvante, Inc., the leader in technology-based clinical trial services for central nervous system (CNS) diseases, today announced that Araclon Biotech has selected MedAvante’s groundbreaking Virgil® Investigative Study Platform for its upcoming Phase 2 trial in prodromal or very mild Alzheimer’s disease (AD).

The Araclon study will investigate the safety, tolerability and immune response of ABvac40, a treatment based on an innovative, specific active immunotherapy against the beta-amyloid 40 protein designed to combat Alzheimer’s disease at its initial stage.

MedAvante will provide the Virgil electronic clinical outcome assessment (eCOA) platform for all clinician-rated outcome assessments to maximize outcome data quality and increase operational efficiency. The Virgil platform, consisting of a tablet device for digital capture with access to the industry’s largest library of electronic rating scales translated to dozens of languages and a tightly integrated web portal for real time data analysis, is currently being used in trials at more than 900 sites in 30 countries.

In addition, MedAvante training will help to standardize the multinational rater cohort, and MedAvante clinicians will perform diagnostic verification and Central Review of the key screening assessments to ensure the quality of administration.

“The ability to detect a sufficient signal to demonstrate efficacy in this type of trial is put at risk by several factors, including the complexity of clinical outcome assessment data, the potential to include ineligible subjects or inflate baseline scoring, and the variability among raters with diverse backgrounds collecting the outcome measures,” said Christopher Randolph, PhD, ABPP-CN, Chief Scientific Officer at MedAvante. “For Araclon Biotech, the Virgil platform and MedAvante clinical services address all these risks.”

“Araclon Biotech is very pleased to enlist MedAvante’s clinical experience and technology leadership for our Phase 2 trial to evaluate the efficacy of the ABvac40 compound,” said Manuel Sarasa, Scientific Director of Araclon Biotech. “In the Phase 1 study, the vaccine demonstrated a good safety and tolerability profile and produced an immune response in a high percentage of patients but does not assess its effectiveness as a treatment.”

“Anticipating our next study, we looked at all options and determined MedAvante brings not only the  most eCOA experience, but can also offer a high degree of clinical expertise on study team and the ability to scale their services to a trial the size of ours,” he said. “The Virgil eCOA platform will ensure that we collect high quality outcome data and MedAvante’s clinical cohort will help us to be certain that we’re enrolling the right patients and screening them accurately.”

MedAvante pioneered electronic source (eSource) data capture in 2009 for use by its own clinicians and since then has garnered more eSource experience than anyone else in the industry – more than 630,000 assessments and eSource data accepted by both the FDA and the EMA in successful regulatory submissions.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE